The Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division

Similar documents
Prescription Opioid Overdose in Oregon: A public health perspective

Presentation Objectives

Oregon Opioid Overdose Prevention Initiative

Oregon Opioid Prescribing Guidelines

Opioid Overdose in Oregon: A Public Health Perspective Mary Borges PDO Coordinator Drew Simpson PDMP Coordinator Oregon Public Health Division

Opioid Overdose in Oregon Report to the Legislature

Central Oregon Pain Standards Task Force

April 26, New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP)

Oregon s PDMP: An epidemiological assist tool

ACCG Mental Health Summit

Opioid Overdose in Oregon

Oregon Prescription Drug Monitoring Program

Harold Rogers Update Melissa McPheeters, PhD, MPH

Building a Comprehensive, Community-driven Prevention Approach to the Opioid Crisis in Maine

PRESCRIPTION DRUG MONITORING PROGRAM

Rule Governing the Prescribing of Opioids for Pain

Meth and Opioid Abuse Prevention Efforts

The Wisconsin Prescription Drug Monitoring Program

Opioid Management of Chronic (Non- Cancer) Pain

The Wisconsin Prescription Drug Monitoring Program. WI PDMP Timeline. PDMP Overview. What is a PDMP? PDMPs Across the Nation. Wisconsin.

EXECUTIVE ORDER TAKING FURTHER ACTIONS TO ADDRESS THE OPIOID OVERDOSE CRISIS

Prescription Monitoring Program (PMP)

Managed Care Pushes for Safer Opioid Oversight

OPIOID PRESCRIBING RULES. May 17, 2017 Webinar

Opioid Data for Local Governments in North Carolina

Defining the Role of the Pharmacist in Combatting the Opioid Epidemic

Opioid Prescribing Improvement Program

Performance of North Carolina's System for Monitoring Prescription Drug Abuse. Session Law , Section 12F.16.(q)

Strategic Prevention Framework for Prescription Drugs

It Takes A Village to Curb the Prescription Opioid Epidemic: Supply healthcare providers with resources to improve patient safety

Prescription Drug Monitoring Program Update. Rebecca R. Poston, BPharm., MHL Program Manager August 26, 2017

Resources Encouraging Safe Prescription Opioid & Naloxone Dispensing: Results from the RESPOND Study

Impact of Opioid Prescribing Rules in Post Acute and Long Term Care

PRESCRIPTION DRUG MONITORING PROGRAM ST. CHARLES COUNTY Q1 2018

Medicare Advantage Outreach and Education Bulletin

Opioid Use and Misuse: History, Trends, And The Oregon Opioid Initiative

Opioid epidemic and PEHP

The Future of Prevention: Addressing the Prescription Drug Abuse and the Opioid/Heroin Epidemic in our Country

Naloxone and Combating the Opioid Epidemic

Six Building Blocks Self-Assessment Questionnaire Workshop Version July 2017

4/26/2018. Bureau of Professional Licensing. MAPS Updates & Opportunities. MAPS Background. Registration. MAPS Update

Opioid Safety Initiative. Thomas Emmendorfer, PharmD Deputy Chief Consultant Pharmacy Benefits Management (PBM) Services

Opioid Abuse in Iowa Rx to Heroin. Iowa Governor s Office of Drug Control Policy January 2016

PRESCRIBING GUIDELINES

Addressing the Opioid Crisis Workgroup: Treatment and Overdose Prevention

Addressing the Opioid Epidemic in Tennessee

Medicare Part D Prescription Opioid Policies for 2019 Information for Pharmacists

The Opioid Crisis: Effectiveness of State Responses

North Carolina, like the rest of the nation, has been experiencing

PDMP Track: Linking and Mapping PDMP Data. Gillian Leichtling Acumentra Health Chris Baumgartner, WA State Dept. of Health

Using the NC Controlled Substances Reporting System to Identify Providers Manifesting Unusual Prescribing Practices

Kentucky All Schedule Prescription Electronic Reporting (KASPER)

STATEMENT. of the. American Medical Association. for the Record. House Committee on Energy and Commerce

Wisconsin Statewide Substance Abuse Prevention Training Wisconsin Dells June 12, 2015

May 25, Drug Overdose Update & Response: Combatting Opioid Overdose

Preventing Opioid Misuse in Texas

A Systems Approach to the Opioid Crisis Safina Koreishi, MD, MPH Mara Laderman, MSPH Lindsay Martin, MSPH

Prescription Drug Monitoring Program

Prescription Drug Abuse and Heroin: Impact on Oregon s Youth and Young Adults

September 1, The Honorable Tom Price, MD Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201

What is the strategy?

CDC s Approach to Addressing the Opioid Overdose Epidemic

Opioid Review and MAT Clinic CDC Guidelines

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2018 (2018Q3)

Kansas Prescription Drug and Opioid Advisory Committee

Safina Koreishi, MD, MPH, Medical Director, Columbia Pacific CCO

Addressing Challenges Together, One Rock at a Time

Illinois Prescription Monitoring Program. Sarah Pointer, Pharm D. Clinical Director of the Illinois Prescription Monitoring Program

MARYLAND BOARD OF PHARMACY

The Opioid Epidemic: The State of the State

Evaluation of the N.C. Prescription

Opioid Safety: Prescribing Guidelines, Quality Measures and Care Coordination Best-Practices

Prescription Drug Abuse Task Force Rx Report Card

Submitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis

House Committee on Energy and Commerce House Committee on Energy and Commerce. Washington, DC Washington, DC 20515

WHY GOOD PAIN MANAGEMENT IS GOOD DRUG ABUSE PREVENTION

COLORADO PRESCRIPTION DRUG MONITORING PROGRAM

Prescribing Opioids in the Opioid Epidemic. Scott Woffinden, PA-C Jason Chapman, JD

4/24/15. New Mexico s Prescription Monitoring Program. Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy. New Mexico and the PMP

ANNUAL REPORT

VIRGINIA S OPIOID & HEROIN OVERDOSE EPIDEMIC

Arkansas Prescription Monitoring Program

October 20, 2016 Scott K. Proescholdbell, MPH. Opioid Overdose and North Carolina s Public Health and Prevention Strategies

Prescription Drug Monitoring Programs and Other State-Level Strategies

Opioid Overdose in Oregon: Coordination & Collaboration Mary Borges Prescription Drug Overdose Prevention Regional Development Coordinator

Prescription Monitoring Program Center for Excellence, Brandeis University. April 10-12, 2012 Walt Disney World Swan Resort

Prescription Opioids in Vermont A DISCUSSION ABOUT LAWS AND GUIDELINES MICHAEL J. KENOSH, MD

Cynthia B. Jones, Director Department of Medical Assistance Services (DMAS)

6/6/2017. First Do No Harm SECTION 1 THE OPIOID CRISIS. Implementing an Opioid Stewardship Program in a HealthCare System OBJECTIVES

North Dakota Board of Pharmacy

Arkansas Department of Health

Pennsylvania Prescription Drug Monitoring Program Trends,

Report to the Legislature: Recommendations on Required Use and Other Uses of the MN Prescription Monitoring Program Database

California. Prescribing and Dispensing Profile. Research current through November 2015.

Harold Rogers Prescription Drug Monitoring Program Regional Meeting-Charleston, SC April 29, 2014 Andrew Holt, PharmD

Massachusetts Responds to the Opioid Epidemic Using Data To Inform Policy and Programs. Monica Bharel, MD MPH Commissioner of Public Health

Greenbrier County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report

Public Policy and Best Practices for Reducing Opioid Harm. State Capital Building, Harrisburg PA June 6, 2018

Implementing Pain and Opioid Management Guidelines in Primary Care Practice

Pharmacy Law Disclosure Statement. Objectives 6/11/2016. I have no conflicts of interest to disclose related to this presentation.

Transcription:

The Oregon Opioid Initiative State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division

Disclosure No disclosures 2

Learning Objectives Learner will be able to demonstrate how to register for the PDMP Learner will be able to name three conditions to look for in a patient report 3

Presentation Outline Oregon Opioid Initiative How PDMP fits in the Oregon Opioid Initiative Purpose of Prescription Drug Monitoring Program Mandated registration how to Patient report for prescribers, pharmacists & public Contents of a report What to look for in a report When to run a report Outcomes Good News 4

The Oregon Opioid Initiative Aim: Reduce deaths, non-fatal overdoses, and harms to Oregonians from prescription opioids, while expanding use of non-opioid pain care REDUCE RISKS TO PATIENTS BY MAKING PAIN TREATMENT SAFER AND MORE EFFECTIVE, emphasizing non-opioid and nonpharmacological treatment 1 2 3 REDUCE HARMS FOR PEOPLE TAKING OPIOIDS AND SUPPORT RECOVERY FROM SUBSTANCE USE DISORDERS by making naloxone rescue and medication-assisted treatment (MAT) more accessible and affordable Protect the community by REDUCING THE NUMBER OF PILLS IN CIRCULATION through implementation of safe prescribing, storage, and disposal practices OPTIMIZE OUTCOMES BY MAKING STATE AND LOCAL DATA AVAILABLE for informing, monitoring, and evaluating policies and targeted interventions 4 5

6 Oregon Opioid Initiative: Strategies

Oregon Health Authority Opioid Initiative Summary Prioritized List Back Condition Benefit Coverage (7/1/2016) Pain Commission Training Pain Education Clinics Statewide Prescribing Guidelines Statewide Dental Prescribing Guidelines Statewide Performance Improvement Project (PIP) CDC Prevention for States Grant Safer Pain Treatment Reduce number of pills 1 2 3 4 Reduce Reduce Harms/ Harms/ Support Support Recovery Recovery Data Availability Naloxone availability Collaboration with law enforcement and EMT Medication Assisted Treatment (MAT) STR Grant Clinical review sub committee prescribing monitoring Public health interactive opioid dashboard CCO PIP > 120 MED and > 90 MED tracked 7

Opioid Prescribing Recommendations Goal: reduce unnecessary prescribing Published March 2016 Chronic Pain Non-cancer Non-palliative Non-end of life 8

After Initiation the Risk of Prolonged Opioid Use Increases by 1 % Per Day After 3 Days Day 3 PDMP & prescribing guidelines can help avoid this 9

Oregon s Prescription Drug Monitoring Program establish and maintain a prescription monitoring program for monitoring and reporting prescription drugs dispensed by pharmacies in Oregon that are classified in schedules II through IV under the federal Controlled Substances Act ORS 431.962, 2009 10

PDMP Information Can Improve Patient Safety & Health Information can reduce: Patient overdose Risk of drug interactions Dependence Drug seeking behavior Over prescribing Drug misuse Drug Diversion Information can increase: Patient safety Conversations about pain Co-prescribing naloxone Dependency screening & SUD tx induction Appropriate pain care Improvement in the continuity of care across the systems of care 11

PDMP: Overview Oregon Health Authority implemented PDMP in 2011 24/7 Web-based access for authorized users Providers and pharmacists can run a query for their patients Patients can request a copy of their report Legislature mandated registration effective July 1, 2018 Allows delegates to sign up and look up on your behalf of Voluntary use Specialized use for law enforcement & judicial purposes Aggregate data are used for research and epidemiologic study 12

13 PDMP Registration- EASY

When to Look up a Patient in PDMP New patient baseline Writing a new or renewal prescription for a controlled substance Monitoring tapering Patient has a history of SUD or mental health tx Patient has multiple providers writing prescriptions Annually Any time you feel like you should look at the patient report 14

PDMP Patient Report List of Schedule II-IV prescriptions dispensed, date, drug, quantity, days supply, MED, refills, RX#, prescriber, pharmacy List of prescribers & location List of pharmacies & location 15

What to Look for in PDMP Patient Report Any of these can provide an opportunity for a conversation with patient and other caregivers: Number and types of drugs dispensed, prescriber, pharmacy Morphine Equivalent Daily Doses per prescribing guideline when MED is >50 consider coprescribing naloxone Prescription dates overlap, early refills Multiple prescribers, multiple pharmacies Benzo & opioid combination Opioid initiation: dose, # of pills after day 3 of initiation, each day increases risk of prolonged use by 1% per day 16

After Initiation the Risk of Prolonged Opioid Use Increases by 1 % Per Day After 3 Days Day 3 PDMP & prescribing guidelines can help avoid this 17

Oregon PDMP: Aggregate Data 7 million prescriptions dispensed annually in Oregon 4,000 prescribers write 80% of scheduled substance prescriptions (66% of top 4,000 prescribers are registered to use the PDMP) 41% of all prescribers have PDMP accounts (Q1 2018) Opioids (e.g. hydrocodone, oxycodone) account for ~50% of prescriptions about 550,000 prescriptions dispensed each quarter in Oregon Benzodiazepines 2 nd most frequent prescription after opioids, amphetamines are 3 rd 18

2015-2017 Oregon Opioid Prescribing: Decreased by 24% Quarterly Fills per 1,000 Residents Oregon Opioid Fills 2011-2017 Q1 2015: 231 opioid fills per 1,000 residents Q1 2018: 175 opioid fills per 1,000 residents 19 Source: Oregon Prescription Drug Monitoring Program healthoregon.org/opioids Data dashboard

Oregon Opioid Prescribing by Age Patients receiving a >120 MED opioid fill Patients per 1,000 residents Age Group 20 Source: Oregon Prescription Drug Monitoring Program. healthoregon.org/opioids Data dashboard

Balance Needs Protect & promote pain management Privacy & Security Inform clinicians Honor Legislative intent Guidelines/ PDMP/ Regulation Control diversion Public education prevention practice Increase SUD treatment referrals Inform public policy 21

For More Information Contact: Katrina Hedberg, MD, MPH: Katrina.hedberg@state.or.us Lisa Bui, MBA: lisa.t.bui@state.or.us Lisa Millet, MSH: lisa.m.millet@state.or.us Web resources: OHA Opioids Website: http://healthoregon.org/opioids Interactive Data Dashboard Community Information Guidelines Oregon Prescription Drug Monitoring Program Website: http://www.orpdmp.com Statewide PIP website: http://www.oregon.gov/oha/hpa/csi/pages/performance- Improvement-Project.aspx HERC website: http://www.oregon.gov/oha/hpa/csi-herc Guideline note 56: Non-interventional treatments for conditions of the back and spine Guideline note 60: Opioids for conditions of the back and spine 22